Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance
Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance
复制标题
DOI：
10.1111/j.1440-1843.2006.00783.x
复制
发表时间：
2006-01-01
期刊：
影响因子：
6.9
通讯作者：
Zhong, NS
中科院分区：
文献类型：
--
作者：
Mo, HY;Zeng, GQ;Zhong, NS
背景：严重急性呼吸系统综合征（SARS）是一种由新型冠状病毒引起的新发现疾病。本研究研究了SARS患者抗SARS冠状病毒（SARS- cov）抗体的纵向分布，并评价了这些抗体的临床意义。方法：采用ELISA法和间接免疫荧光法检测98例SARS患者335份系列血清中抗SARS冠状病毒IgG和IgM。对18例患者进行血清抗体分析，并在症状出现后7 - 720天进行抗体中和试验。结果：发病后1 ~ 7天、8 ~ 14天、15 ~ 21天、22 ~ 28天、29 ~ 60天、61 ~ 90天、91 ~ 180天、181 ~ 720天，ELISA检测IgG/IgM阳性率分别为0/0、45.4/39.4、88.6/71.4、96/88、100/48.6、100/30.9、100/17.1、100/ 0%。发病前7天未检出抗体，但IgG滴度在第1.5天急剧上升，在第60天达到峰值，并一直保持在高滴度至180天，此后逐渐下降至720天。IgM在第15天检测到，并迅速达到峰值，然后逐渐下降，直到180天无法检测到。在SARS患者恢复期血清中发现了中和性病毒抗体。结论：可检测到的IgG抗体和中和病毒抗体的持续时间长达720天，表明SARS患者可在长达2年的时间内免受复发性SARS冠状病毒感染。
Background: Severe acute respiratory syndrome (SARS) is a newly discovered disease caused by a novel coronavirus. The present study studied the longitudinal profile of antibodies against SARS-coronavirus (SARS-CoV) in SARS patients and evaluated the clinical significance of these antibodies.Methods: Two methods, ELISA and indirect immunofluorescent assay, were used for the detection of the anti-SARS-CoV IgG and IgM in 335 serial sera from 98 SARS patients. In 18 patients, serum antibody profiles were investigated and antibody neutralization tests were performed from 7 to 720 days after the onset of symptoms.Results: The ratios of positive IgG/IgM by ELISA were 0/0, 45.4/39.4, 88.6/71.4, 96/88, 100/48.6, 100/30.9, 100/17.1, 100/0 per cent, respectively, on 1-7, 8-14, 15-21, 22-28, 29-60, 61-90, 91-180 and 181-720 days after the onset of symptoms. Antibodies were not detected within the first 7 days of illness, but IgG titre increased dramatically on day 1.5, reaching a peak on day 60, and remained high until day 180 from when it declined gradually until day 720. IgM was detected on day 15 and rapidly reached a peak, then declined gradually until it was undetectable on day 180. Neutralizing viral antibodies were demonstrated in the convalescence sera from SARS patients.Conclusion: The persistence of detectable IgG antibodies and neutralizing viral antibodies for up to 720 days suggest that SARS patients may be protected from recurrent SARS-CoV infection for up to 2 years.